Cargando…
CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome
BACKGROUND: CCR5 is a motility chemokine receptor implicated in tumor progression, whose activation and subsequent endocytosis may identify highly aggressive breast cancer cell subtypes likely to spread into the circulatory system. METHODS: The MDA-MB-231 cell line was used to model and visualize CC...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125938/ https://www.ncbi.nlm.nih.gov/pubmed/35606863 http://dx.doi.org/10.1186/s13058-022-01528-w |
_version_ | 1784712035620093952 |
---|---|
author | Raghavakaimal, Ashvathi Cristofanilli, Massimo Tang, Cha-Mei Alpaugh, R. K. Gardner, Kirby P. Chumsri, Saranya Adams, Daniel L. |
author_facet | Raghavakaimal, Ashvathi Cristofanilli, Massimo Tang, Cha-Mei Alpaugh, R. K. Gardner, Kirby P. Chumsri, Saranya Adams, Daniel L. |
author_sort | Raghavakaimal, Ashvathi |
collection | PubMed |
description | BACKGROUND: CCR5 is a motility chemokine receptor implicated in tumor progression, whose activation and subsequent endocytosis may identify highly aggressive breast cancer cell subtypes likely to spread into the circulatory system. METHODS: The MDA-MB-231 cell line was used to model and visualize CCR5 activation by stimulation with RANTES, in an effort to quantify CCR5 endocytosis from the cell surface to the perinuclear space. CCR5 expression was then examined in tumor-associated cells (TACs), consisting of circulating tumor cells and circulating stromal cells, isolated from the peripheral blood of 54 metastatic breast cancer (mBC) patients to evaluate these CCR5 pooling patterns as they relate to progression and survival over 2 years. RESULTS: In MB231 experiments, it was observed that CCR5 formed ~ 1 micron clusters identified as “CCR5 pools” on the surface of the cell, which in the presence of RANTES were endocytosed and translocated to the cell cytoplasm. When TACs from patients were analyzed, CCR5 pools were observed on the cell surface and translocating to the nuclear area, with CCR5 also having a positive statistical correlation between increased numbers of TACs and increased CCR5 pools on the cells. Further, it was determined that patients with very high numbers of CCR5 (> 10 CCR5 pools), specifically in the circulating stromal cells, were associated with worse progression-free survival (hazard ratio = 4.5, p = 0.002) and worse overall survival (hazard ratio = 3.7, p = 0.014). CONCLUSIONS: Using a liquid biopsy approach, we evaluated two populations of tumor-associated cells emanating from primary tumors, with data suggesting that upregulation of the motility chemokine CCR5 in TACs provides clinically relevant opportunities for treating and tracking drug targetable receptors in mBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-022-01528-w. |
format | Online Article Text |
id | pubmed-9125938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91259382022-05-24 CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome Raghavakaimal, Ashvathi Cristofanilli, Massimo Tang, Cha-Mei Alpaugh, R. K. Gardner, Kirby P. Chumsri, Saranya Adams, Daniel L. Breast Cancer Res Research Article BACKGROUND: CCR5 is a motility chemokine receptor implicated in tumor progression, whose activation and subsequent endocytosis may identify highly aggressive breast cancer cell subtypes likely to spread into the circulatory system. METHODS: The MDA-MB-231 cell line was used to model and visualize CCR5 activation by stimulation with RANTES, in an effort to quantify CCR5 endocytosis from the cell surface to the perinuclear space. CCR5 expression was then examined in tumor-associated cells (TACs), consisting of circulating tumor cells and circulating stromal cells, isolated from the peripheral blood of 54 metastatic breast cancer (mBC) patients to evaluate these CCR5 pooling patterns as they relate to progression and survival over 2 years. RESULTS: In MB231 experiments, it was observed that CCR5 formed ~ 1 micron clusters identified as “CCR5 pools” on the surface of the cell, which in the presence of RANTES were endocytosed and translocated to the cell cytoplasm. When TACs from patients were analyzed, CCR5 pools were observed on the cell surface and translocating to the nuclear area, with CCR5 also having a positive statistical correlation between increased numbers of TACs and increased CCR5 pools on the cells. Further, it was determined that patients with very high numbers of CCR5 (> 10 CCR5 pools), specifically in the circulating stromal cells, were associated with worse progression-free survival (hazard ratio = 4.5, p = 0.002) and worse overall survival (hazard ratio = 3.7, p = 0.014). CONCLUSIONS: Using a liquid biopsy approach, we evaluated two populations of tumor-associated cells emanating from primary tumors, with data suggesting that upregulation of the motility chemokine CCR5 in TACs provides clinically relevant opportunities for treating and tracking drug targetable receptors in mBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-022-01528-w. BioMed Central 2022-05-23 2022 /pmc/articles/PMC9125938/ /pubmed/35606863 http://dx.doi.org/10.1186/s13058-022-01528-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Raghavakaimal, Ashvathi Cristofanilli, Massimo Tang, Cha-Mei Alpaugh, R. K. Gardner, Kirby P. Chumsri, Saranya Adams, Daniel L. CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome |
title | CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome |
title_full | CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome |
title_fullStr | CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome |
title_full_unstemmed | CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome |
title_short | CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome |
title_sort | ccr5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125938/ https://www.ncbi.nlm.nih.gov/pubmed/35606863 http://dx.doi.org/10.1186/s13058-022-01528-w |
work_keys_str_mv | AT raghavakaimalashvathi ccr5activationandendocytosisincirculatingtumorderivedcellsisolatedfromthebloodofbreastcancerpatientsprovideinformationaboutclinicaloutcome AT cristofanillimassimo ccr5activationandendocytosisincirculatingtumorderivedcellsisolatedfromthebloodofbreastcancerpatientsprovideinformationaboutclinicaloutcome AT tangchamei ccr5activationandendocytosisincirculatingtumorderivedcellsisolatedfromthebloodofbreastcancerpatientsprovideinformationaboutclinicaloutcome AT alpaughrk ccr5activationandendocytosisincirculatingtumorderivedcellsisolatedfromthebloodofbreastcancerpatientsprovideinformationaboutclinicaloutcome AT gardnerkirbyp ccr5activationandendocytosisincirculatingtumorderivedcellsisolatedfromthebloodofbreastcancerpatientsprovideinformationaboutclinicaloutcome AT chumsrisaranya ccr5activationandendocytosisincirculatingtumorderivedcellsisolatedfromthebloodofbreastcancerpatientsprovideinformationaboutclinicaloutcome AT adamsdaniell ccr5activationandendocytosisincirculatingtumorderivedcellsisolatedfromthebloodofbreastcancerpatientsprovideinformationaboutclinicaloutcome |